title: Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient management.
abstract: For patients with advanced indolent non-Hodgkin's lymphoma (NHL) or elderly patients with mantle cell lymphoma (MCL), the recently reported results of the German StiL NHL-1 2003 and the international BRIGHT phase III trials showed that, as first-line treatment, the combination of bendamustine and rituximab is at least as effective as rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone or rituximab/cyclophosphamide/vincristine/prednisone, possibly with a better therapeutic index. Bendamustine is therefore increasingly used in clinical practice. Because bendamustine has been used for many years in Germany and in Switzerland, our institutions have had extensive experience with bendamustine, both as a single agent and in combination with rituximab. In this comprehensive review, we summarize the most important clinical data from phase II/III trials with bendamustine in patients with indolent NHL and MCL, both in the relapsed/refractory setting and in the first-line setting. In addition, this review provides practical advice on how to optimally manage bendamustine therapy in patients with NHL.
authors.affiliation: Department of Hematology, Oncology, and Palliative Care, Schwarzwald-Baar Clinic, Academic Teaching Hospital, University of Freiburg, Villingen-Schwenningen, Germany. wolfram.brugger@sbk-vs.de
authors.forename: Wolfram
authors.initials: W
authors.lastname: Brugger
authors.forename: Michele
authors.initials: M
authors.lastname: Ghielmini
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000069461:Bendamustine Hydrochloride; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use; D005858:Germany; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy* / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D009588:Nitrogen Mustard Compounds; D000069283:Rituximab; D003520:Cyclophosphamide; D000069461:Bendamustine Hydrochloride
keywords: Bendamustine; Clinical practice; Non-Hodgkin's lymphoma
references.citation: J Clin Oncol. 2012 Sep 10;30(26):3209-16
references.pmid: 22869884
references.citation: Ann Pharmacother. 2009 Nov;43(11):1903-6
references.pmid: 19809007
references.citation: Hematol Oncol Stem Cell Ther. 2011;4(4):157-60
references.pmid: 22198186
references.citation: J Clin Oncol. 2013 Apr 20;31(12):1496-8
references.pmid: 23530108
references.citation: J Clin Oncol. 2008 Sep 20;26(27):4473-9
references.pmid: 18626004
references.citation: Cancer Chemother Pharmacol. 2010 Nov;66(6):1039-49
references.pmid: 20140617
references.citation: J Clin Oncol. 2009 Mar 10;27(8):1202-8
references.pmid: 19204203
references.citation: Lancet. 2013 Apr 6;381(9873):1203-10
references.pmid: 23433739
references.citation: Cancer. 2010 Jan 1;116(1):106-14
references.pmid: 19890959
references.citation: Blood. 2011 Mar 10;117(10):2807-12
references.pmid: 21239695
references.citation: J Clin Oncol. 2011 Sep 10;29(26):3559-66
references.pmid: 21844497
references.citation: Dermatol Online J. 2010 Jul 15;16(7):1
references.pmid: 20673529
references.citation: J Clin Oncol. 2013 Apr 10;31(11):1442-9
references.pmid: 23401442
references.citation: Drugs Aging. 2010 Mar 1;27(3):211-38
references.pmid: 20210368
references.citation: Leuk Res. 2011 Nov;35(11):e223-4
references.pmid: 21824654
references.citation: Clin Lymphoma Myeloma Leuk. 2010 Feb;10(1):21-7
references.pmid: 20223726
references.citation: J Clin Oncol. 2009 Mar 20;27(9):1492-501
references.pmid: 19224851
references.citation: J Clin Oncol. 2008 Jan 10;26(2):204-10
references.pmid: 18182663
references.citation: Clin Lymphoma Myeloma Leuk. 2010 Dec;10(6):452-7
references.pmid: 21189660
references.citation: Int J Hematol. 2012 May;95(5):588-91
references.pmid: 22419099
references.citation: Semin Hematol. 2011 Apr;48 Suppl 1:S4-11
references.pmid: 21530771
references.citation: J Clin Oncol. 2005 May 20;23(15):3383-9
references.pmid: 15908650
references.citation: Ann Hematol. 2012 Apr;91(4):643-4
references.pmid: 21811782
references.citation: J Clin Oncol. 2009 Sep 10;27(26):4378-84
references.pmid: 19652068
references.citation: Cancer Control. 2012 Jul;19(3):245-7
references.pmid: 22710900
references.citation: J Clin Oncol. 2011 Sep 1;29(25):3389-95
references.pmid: 21810687
references.citation: Leuk Lymphoma. 2013 Aug;54(8):1640-6
references.pmid: 23151046
references.citation: Curr Oncol. 2012 Jun;19(3):160-8
references.pmid: 22670095
references.citation: Blood. 2011 Sep 22;118(12):3419-25
references.pmid: 21816830
references.citation: Ann Oncol. 2000 Jun;11(6):729-34
references.pmid: 10942063